BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 37013957)

  • 1. Using Renin Activity to Guide Mineralocorticoid Receptor Antagonist Therapy in Patients with Low Renin and Hypertension.
    Mansur A; Vaidya A; Turchin A
    Am J Hypertens; 2023 Jul; 36(8):455-461. PubMed ID: 37013957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mineralocorticoid Receptor Antagonists Decrease the Rates of Positive Screening for Primary Aldosteronism.
    Tezuka Y; Turcu AF
    Endocr Pract; 2020 Dec; 26(12):1416-1424. PubMed ID: 33471733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism.
    Tezuka Y; Turcu AF
    Front Endocrinol (Lausanne); 2021; 12():625457. PubMed ID: 33841329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent progress in the diagnosis and treatment of primary aldosteronism.
    Yoshida Y; Shibata H
    Hypertens Res; 2023 Jul; 46(7):1738-1744. PubMed ID: 37198444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Reversal of Renin Suppression With Long-Term Renal Outcome in Medically Treated Primary Aldosteronism.
    Katsuragawa S; Goto A; Shinoda S; Inoue K; Nakai K; Saito J; Nishikawa T; Tsurutani Y
    Hypertension; 2023 Sep; 80(9):1909-1920. PubMed ID: 37449450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary aldosteronism in hypertensive patients: clinical implications and target therapy.
    Papanastasiou L; Markou A; Pappa T; Gouli A; Tsounas P; Fountoulakis S; Kounadi T; Tsiama V; Dasou A; Gryparis A; Samara C; Zografos G; Kaltsas G; Chrousos G; Piaditis G
    Eur J Clin Invest; 2014 Aug; 44(8):697-706. PubMed ID: 24909545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism.
    Pecori A; Buffolo F; Burrello J; Mengozzi G; Rumbolo F; Avataneo V; D'Avolio A; Rabbia F; Bertello C; Veglio F; Mulatero P; Monticone S
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3655-e3664. PubMed ID: 33942084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Mineralocorticoid and AT1 Receptor Antagonism on The Aldosterone-Renin Ratio In Primary Aldosteronism-the EMIRA Study.
    Rossi GP; Ceolotto G; Rossitto G; Maiolino G; Cesari M; Seccia TM
    J Clin Endocrinol Metab; 2020 Jun; 105(6):. PubMed ID: 32067030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of esaxerenone on blood pressure, urinary albumin excretion, serum levels of NT-proBNP, and quality of life in patients with primary aldosteronism.
    Yoshida Y; Fujiwara M; Kinoshita M; Sada K; Miyamoto S; Ozeki Y; Iwamoto M; Mori Y; Nagai S; Matsuda N; Noguchi T; Okamoto M; Gotoh K; Masaki T; Shibata H
    Hypertens Res; 2024 Jan; 47(1):157-167. PubMed ID: 37717115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mild primary aldosteronism (PA) followed by overt PA are possibly the most common forms of low renin hypertension: a single-center retrospective study.
    Luo Q; Li N; Wang M; Yao X; Heizhati M; Zhang D; Zhou K; Wang G; Hu J; Zhu B
    J Hum Hypertens; 2020 Sep; 34(9):633-640. PubMed ID: 31792441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adrenal Vein Sampling Lateralization Despite Mineralocorticoid Receptor Antagonists Exposure in Primary Aldosteronism.
    Nanba AT; Wannachalee T; Shields JJ; Byrd JB; Rainey WE; Auchus RJ; Turcu AF
    J Clin Endocrinol Metab; 2019 Feb; 104(2):487-492. PubMed ID: 30239792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diagnosis and treatment outcome in primary aldosteronism based on a retrospective analysis of 187 cases].
    Szücs N; Gláz E; Varga I; Tóth M; Kiss R; Patócs A; Jakab C; Perner F; Járay J; Horányi J; Dabasi G; Molnár F; Major L; Füto L; Rácz K; Tulassay Z
    Orv Hetil; 2006 Jan; 147(2):51-9. PubMed ID: 16509213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regression of left ventricular hypertrophy in patients with primary aldosteronism/low-renin hypertension on low-dose spironolactone.
    Ori Y; Chagnac A; Korzets A; Zingerman B; Herman-Edelstein M; Bergman M; Gafter U; Salman H
    Nephrol Dial Transplant; 2013 Jul; 28(7):1787-93. PubMed ID: 23378418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of mineralocorticoid and AT-1 receptor antagonism on the aldosterone-renin ratio (ARR) in primary aldosteronism patients (EMIRA Study): rationale and design.
    Rossitto G; Cesari M; Ceolotto G; Maiolino G; Seccia TM; Rossi GP
    J Hum Hypertens; 2019 Feb; 33(2):167-171. PubMed ID: 30518805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of Atrial Fibrillation and Mineralocorticoid Receptor Activity in Patients With Medically and Surgically Treated Primary Aldosteronism.
    Hundemer GL; Curhan GC; Yozamp N; Wang M; Vaidya A
    JAMA Cardiol; 2018 Aug; 3(8):768-774. PubMed ID: 30027227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 19-nor-deoxycorticosterone excretion in primary aldosteronism and low renin hypertension.
    Griffing GT; Dale SL; Holbrook MM; Melby JC
    J Clin Endocrinol Metab; 1983 Feb; 56(2):218-21. PubMed ID: 6337172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malignant Hypertension and Bilateral Primary Aldosteronism.
    Murai S; Kakeshita K; Imamura T; Koike T; Fujioka H; Yamazaki H; Kinugawa K
    Intern Med; 2023 Sep; 62(18):2675-2680. PubMed ID: 36725041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of cardiovascular disease risk and changes in renin levels by mineralocorticoid receptor antagonists in patients with primary aldosteronism.
    Nomura M; Kurihara I; Itoh H; Ichijo T; Katabami T; Tsuiki M; Wada N; Yoneda T; Sone M; Oki K; Yamada T; Kobayashi H; Tamura K; Ogawa Y; Inagaki N; Yamamoto K; Otsuki M; Yabe D; Izawa S; Takahashi Y; Suzuki T; Yasoda A; Tanabe A; Naruse M;
    Hypertens Res; 2022 Sep; 45(9):1476-1485. PubMed ID: 35764671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testing for Primary Aldosteronism and Mineralocorticoid Receptor Antagonist Use Among U.S. Veterans : A Retrospective Cohort Study.
    Cohen JB; Cohen DL; Herman DS; Leppert JT; Byrd JB; Bhalla V
    Ann Intern Med; 2021 Mar; 174(3):289-297. PubMed ID: 33370170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A controlled trial of percutaneous adrenal arterial embolization for hypertension in patients with idiopathic hyperaldosteronism.
    Zhou Y; Wang X; Hou J; Wan J; Yang Y; Liu S; Luo T; Liu Q; Xue Q; Wang P
    Hypertens Res; 2024 Feb; 47(2):311-321. PubMed ID: 37644179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.